Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 17/20 | 0.53 |
| ▸ | PTGER4 | P35408 | 16/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1057878 | 0.88 | PTGER2 (0.55) | PTGER2PTGER4HRH1 | |
| SCHEMBL7068955 | 0.87 | PTGER2 (0.59) | PTGER2PTGER4 | |
| SCHEMBL1083324 | 0.87 | PTGER2 (0.59) | PTGER2PTGER4 | |
| SCHEMBL1055319 | 0.87 | PTGER2 (0.59) | PTGER2PTGER4 | |
| SCHEMBL1057442 | 0.85 | PTGER2 (0.51) | PTGER2PTGER4HRH1CYP4A11 | |
| SCHEMBL4627704 | 0.84 | PTGER2 (0.71) | PTGER2PTGER4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1055967 | 0.83 | PTGER2 (0.49) | PTGER2PTGER4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1057576 | 0.83 | PTGER2 (0.55) | PTGER2PTGER4HRH1CYP4A11 | |
| SCHEMBL1058229 | 0.81 | PTGER2 (0.47) | PTGER2PTGER4HRH1 | |
| SCHEMBL1050677 | 0.80 | PTGER2 (0.47) | PTGER2PTGER4HRH1CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863312-B2 | Pyrazolidinone compounds as ligands of the prostaglandin EP2 and/or EP4 receptors | MERCK SERONO SA (CH) | 2011-01-04 | — | — | US | disclosed |
| US-20080234346-A1 | PYRAZALIDINONE COMPOUNDS AS LIGANDS OF THE PROSTAGLANDIN EP2 AND/OR EP4 RECEPTORS | LABORATOIRES SERONO S.A. (CH) | 2008-09-25 | — | — | US | disclosed |
| US-7410991-B2 | Pyrazolidinone compounds as ligands of the prostaglandin EP2 and/or EP4 receptors | LABORATOIRES SERONO S.A. (CH) | 2008-08-12 | — | — | US | disclosed |
| EP-1439837-B1 | PYRAZOLIDINONE COMPOUNDS AS LIGANDS OF THE PROSTAGLANDIN EP2 AND/OR EP4 RECEPTORS | SERONO LAB (CH) | 2008-04-09 | — | — | EP | disclosed |
| US-20040254233-A1 | Pyrazolidinone compounds as ligands of the prostaglandin ep2 and/or ep4 receptors | MERCK SERONO SA (CH) | 2004-12-16 | — | — | US | disclosed |
| EP-1439837-A1 | PYRAZOLIDINONE COMPOUNDS AS LIGANDS OF THE PROSTAGLANDIN EP2 AND/OR EP4 RECEPTORS | Applied Research Systems ARS Holding N.V. (AN) | 2004-07-28 | — | — | EP | disclosed |
| WO-2003035064-A1 | PYRAZOLIDINONE COMPOUNDS AS LIGANDS OF THE PROSTAGLANDIN EP2 AND/OR EP4 RECEPTORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254233-A1 | Pyrazolidinone compounds as ligands of the prostaglandin ep2 and/or ep4 receptors | PTGER4, PTGER2, PTGER1 | PTGER2 2/4885PTGER4 1/4885SLC6A2 4681/4885 |
| US-20080234346-A1 | PYRAZALIDINONE COMPOUNDS AS LIGANDS OF THE PROSTAGLANDIN EP2 AND/OR EP4 RECEPTORS | PTGER4, PTGER2, PTGER1 | PTGER2 2/4885PTGER4 1/4885SLC6A2 4684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.